Agilon Health, Inc. AGL
80.73
4.90
6.46%
as of 25 Sep
- Market cap
- $1.3B
- P/E
- 0.0×
Follow AGL
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.30 | 0.02 | 0.05 | 0.07 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(31.25) | 5.53 | (13.89) | (23.52) | |
P/B ratio |
7.87 | 0.72 | 2.25 | 1.39 | |
Price to Tangible BV |
10.70 | 1.10 | 4.68 | 2.07 | |
EV/Sales |
0.26 | (0.02) | 0.01 | 0.03 | |
EV/EBITDA |
0.00 | 0.35 | 0.00 | 0.00 | |
EV/Operating CF |
(21.64) | 2.83 | (0.33) | (2.70) | |
EV/FCF |
(14.75) | 1.66 | (0.24) | (1.62) | |
Quick Ratio |
1.00 | 0.95 | 0.89 | 1.01 | |
Current Ratio |
1.08 | 1.04 | 1.02 | 1.08 | |
Net Debt/EBITDA |
(12.18) | (25.31) | 1.34 | 2.23 | |
Debt/Assets |
1.90% | 2.00% | 2.75% | 2.19% | |
Debt/Equity |
0.13 | 0.17 | 0.28 | 0.11 | |
Asset Turnover |
3.58 | 3.39 | 3.95 | 3.19 | |
Operating CF/Net income |
(3.19) | 0.49 | 0.11 | 0.16 | |
Capex/Depreciation |
(0.63) | (0.46) | (1.40) | (2.23) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
5.92% | 3.82% | 3.83% | 3.92% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.05 | 0.06 | |
Share Based Compensation of Revenue |
1.59% | 0.44% | 0.61% | 0.52% | |
Graham Net Nets |
0.03 | (0.02) | (0.17) | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.28%) | (272.44%) | (137.84%) | (72.82%) | |
Free Cash Flow Yield |
(5.92%) | (65.04%) | (52.18%) | (26.84%) | |
Revenue per Share |
89.48 | 85.58 | 94.78 | 86.58 | |
Operating CF per Share |
(3.43) | 1.43 | (1.24) | (1.09) | |
Capex per Share |
(0.26) | (0.19) | (0.59) | (1.00) | |
Free Cash Flow per Share |
(3.69) | 1.24 | (1.83) | (2.09) | |
Cash per Share |
15.40 | 18.25 | 17.22 | 18.75 | |
Shareholders Equity per Share |
13.62 | 10.93 | 7.65 | 18.46 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
13.62 | 10.93 | 7.65 | 18.46 | |
Free Cash Flow |
(61.60) | 20.60 | (30.29) | (34.69) | |
Working Capital |
106.19 | 48.85 | 20.21 | 98.15 | |
Capital Expenditures |
(4.31) | (3.13) | (9.76) | (16.53) | |
Net Current Asset Value |
54.73 | (2.33) | (47.86) | 47.86 | |
EV/EBIT |
0.00 | 0.32 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.01 | |
Net Profit Margin |
1.20% | 3.44% | (12.03%) | (7.68%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1,053.48 | 1,069.67 | 845.42 | 1,157.75 | |
Average Payables |
223.41 | 214.59 | 173.91 | 182.00 | |
Average Assets |
1,652.12 | 1,718.90 | 1,502.64 | 1,843.83 | |
Average Common Equity |
318.23 | 340.84 | 298.84 | 440.47 |
Columns are period end dates